{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T02:31:19Z","timestamp":1783391479596,"version":"3.54.6"},"reference-count":11,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Thymic epithelial tumors, including thymoma and thymic carcinoma, are rare malignancies of the mediastinum, often associated with poor long-term outcomes in advanced stages. Surgical resection and platinum-based chemotherapy have been the cornerstone of management for resectable and advanced, unresectable disease, respectively, with the use of neoadjuvant chemotherapy alone or chemotherapy combined with radiation in specific cases. We report the case of a patient diagnosed with advanced hormone receptor-positive\/HER2-positive breast cancer and a synchronous, advanced thymic carcinoma. After completion of standard-of-care adjuvant dose-dense chemotherapy for her breast cancer, interval imaging revealed marked reduction in the size of the thymic mass with subsequent surgical resection noting a complete pathologic response. The patient remained disease-free for four years before developing recurrence of the thymic carcinoma. This case highlights the potential effectiveness of dose-dense chemotherapy in the treatment of thymic malignancies. Locally advanced and metastatic thymic carcinoma remains challenging to manage, making this patient\u2019s response particularly noteworthy. Given that the therapeutic strategies for thymic tumors have remained largely unchanged in recent years, dose-dense chemotherapy may represent a promising addition to the current treatment paradigm, though further investigation is needed to evaluate its broader applicability.<\/jats:p>","DOI":"10.3389\/fonc.2026.1732776","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T06:56:49Z","timestamp":1772089009000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Complete remission of thymic carcinoma using dose-dense chemotherapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Mae","family":"Shu","sequence":"first","affiliation":[{"name":"Indiana University School of Medicine","place":["Indianapolis, IN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tieying","family":"Hou","sequence":"additional","affiliation":[{"name":"Clinical Pathology & Laboratory Medicine, Indiana University School of Medicine","place":["Indianapolis, IN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy M.","family":"Rissing","sequence":"additional","affiliation":[{"name":"Radiology & Imaging Sciences Practice, Indiana University School of Medicine","place":["Indianapolis, IN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Maniar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center","place":["Indianapolis, IN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Sr","given":"Patrick J.","family":"Loehrer","sequence":"additional","affiliation":[{"name":"Department of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center","place":["Indianapolis, IN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ejcts.2009.05.038","article-title":"Thymoma and thymic carcinoma","volume":"37","author":"Venuta","year":"2010","journal-title":"Eur J Cardio-Thoracic Surgery"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.21037\/med.2019.04.03","article-title":"Induction chemotherapy for locally advanced thymic epithelial tumors: consideration from the RYTHMIC prospective cohort","volume":"3","author":"Nakagawa","year":"2019","journal-title":"Mediastinum"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00178","article-title":"Tailored dose-dense versus standard adjuvant chemotherapy for high-risk early breast cancer: end-of-study results of the randomized PANTHER trial","volume":"42","author":"Matikas","year":"2024","journal-title":"JCO"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1159\/000148914","article-title":"Dose-dense chemotherapy: principles, clinical results and future perspectives","volume":"3","author":"Citron","year":"2008","journal-title":"Breast Care"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0733","article-title":"The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER2\/neu overexpressed\/amplified breast cancer","volume":"26","author":"Dang","year":"2008","journal-title":"JCO"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2003.12.010","article-title":"Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable Malignant thymomas","volume":"44","author":"Kim","year":"2004","journal-title":"Lung Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/sj.bjc.6605731","article-title":"A phase II trial of dose-dense chemotherapy, followed by surgical resection and\/or thoracic radiotherapy, in locally advanced thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9606)","volume":"103","author":"Kunitoh","year":"2010","journal-title":"Br J Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2015(12)03","article-title":"Chemotherapy and prognosis in advanced thymic carcinoma patients","volume":"70","author":"Song","year":"2015","journal-title":"Clinics"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318292c41e","article-title":"A prospective phase II trial of induction chemotherapy with docetaxel\/cisplatin for Masaoka stage III\/IV thymic epithelial tumors","volume":"8","author":"Park","year":"2013","journal-title":"J Thorac Oncol Jul"},{"key":"B10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jtcvs.2013.08.061","article-title":"Neoadjuvant chemoradiotherapy for locally advanced thymic tumors: a phase II, multi-institutional clinical trial","volume":"147","author":"Korst","year":"2014","journal-title":"J Thorac Cardiovasc Surg Jan"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2012.05.108","article-title":"HER family receptor and ligand status in thymic carcinoma","volume":"77","author":"Weissferdt","year":"2012","journal-title":"Lung Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1732776\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T06:56:55Z","timestamp":1772089015000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1732776\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":11,"alternative-id":["10.3389\/fonc.2026.1732776"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1732776","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"article-number":"1732776"}}